Bordetella pertussis in sporadic and outbreak settings in Alberta, Canada, July 2004 – December 2012

BMC Infectious Diseases

Steven J Drews¹  Linda Chui⁴  Vincent Li⁴  Shamir N Mukhi³  Lin Yan⁴  Kimberley Simmonds⁶  Bonita E Lee²  Christina Ferrato⁵  Sumana Fathima⁵ 

[1] Department of Microbiology, Immunology and Infectious Diseases, University of Calgary, Calgary, AB, Canada;University of Alberta, Edmonton, AB, Canada;Canadian Network for Public Health Intelligence, Public Health Agency of Canada, Winnipeg, MB, Canada;Provincial Laboratory for Public Health (ProvLab) Edmonton Site, Edmonton, AB, Canada;Provincial Laboratory for Public Health (ProvLab) Calgary Site, Calgary, AB, Canada;University of Calgary, Department of Community Health Sciences, Calgary, AB, Canada

关键词: Epidemiology;    Outbreaks;    Pertussis;   

Others  :  1134878
DOI  :  10.1186/1471-2334-14-48

 received in 2013-09-23, accepted in 2014-01-27,  发布年份 2014

【 摘 要 】

Background

ProvLab Alberta provides all laboratory testing for Bordetella pertussis including sporadic cases and outbreak investigations through collaborations with provincial public health partners. We describe B. pertussis activity in Alberta from July 2004 to December 2012.

Methods

Laboratory testing for pertussis was analyzed using interpreted laboratory data that was generated by DIAL, a secure web-based platform. Duplicate specimens from the same individual ≤90 days were excluded to generate a case-based dataset. Immunization status of confirmed pertussis cases from the provincial immunization repository was reviewed.

Results

Overall, 7.1% of suspected pertussis cases tested positive with a higher positivity rate in outbreak as compared to sporadic setting. Annual variations in sporadic pertussis cases were observed across the province with higher positivity rates in 2005, 2008, 2009 and 2012. A significantly higher positivity rate was observed in a northern region of Alberta. While the positivity rate in sporadic setting was highest in adolescents aged 10 to <15 years old (14.8%), population-based disease burden was highest in young children <5 years old. Of the 81.6% (n = 1,348) pertussis cases with immunization records, 48.3% were up-to-date with immunization. The pertussis cases that were up-to-date with their immunization were older (median age 12.9 years) as compared to those with incomplete (median age 9.7 years) or no pertussis immunization (median age 3.8 years).

Conclusions

Cyclic pattern of annual pertussis activity with geographic variation was observed in Alberta with no obvious case finding effect from outbreak investigations. The high positivity rates in adolescents suggested an underestimation of disease burden in this age group.

【 授权许可】

   
2014 Fathima et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 5.

【 参考文献 】

• [1]Munoz FM: Pertussis in infants, children, and adolescents: diagnosis, treatment, and prevention. Semin Pediatr Infect Dis 2006, 17:14-19.
• [2]Wood N, McIntyre P: Pertussis: review of epidemiology, diagnosis, management and prevention. Paediatr Respir Rev 2008, 9:201-211.
• [3]Spector TB, Maziarz EK: Pertussis. Med Clin North Am 2013, 97:537-552.
• [4]Snyder J, Fisher D: Pertussis in childhood. Pediatr Rev 2012, 33:412-420.
• [5]Preziosi MP, Halloran ME: Effects of pertussis vaccination on disease: vaccine efficacy in reducing clinical severity. Clin Infect Dis 2003, 37:772-779.
• [6]Statistics Canada. CANSIM (database): Table 051–0001 - Estimates of population, by age group and sex for July 1,Canada,provinces and territories, annual (person unless otherwise noted). 2013. http://www5.statcan.gc.ca/cansim/a05?lang=eng&id=0510001 webcite Accessed April 28
• [7]Alberta Health: Alberta Immunization Manual (2007) Appendix 2– History of biologicals administered in Alberta. 2013. http://www.health.alberta.ca/documents/AIP-Appendices.pdf webcite Accessed June 25
• [8]National Advisory Committee on Immunization PHAoC: Canadian Immunization Guide (2006). 2013. http://www.phac-aspc.gc.ca/publicat/cig-gci/index-eng.php webcite. Accessed May 29
• [9]Broutin H, Guegan JF, Elguero E, Simondon F, Cazelles B: Large-scale comparative analysis of pertussis population dynamics: periodicity, synchrony, and impact of vaccination. Am J Epidemiol 2005, 161:1159-1167.
• [10]Alberta Health and Wellness: Public Health Notifiable Disease Management Guidelines (2011). 2012. http://www.health.alberta.ca/documents/Guidelines-Pertussis-2011.pdf webcite Accessed April 28.
• [11]Reischl U, Lehn N, Sanden GN, Loeffelholz MJ: Real-time PCR assay targeting IS481 of Bordetella pertussis and molecular basis for detecting Bordetella holmesii. J Clin Microbiol 2001, 39:1963-1966.
• [12]Mukhi SN, May-Hadford J, Plitt S, Preiksaitis J, Lee B: DIAL: A Platform for real-time Laboratory Surveillance. Online J Public Health Inform 2010., 2
• [13]Van der ZA, Agterberg C, Peeters M, Mooi F, Schellekens J: A clinical validation of Bordetella pertussis and Bordetella parapertussis polymerase chain reaction: comparison with culture and serology using samples from patients with suspected whooping cough from a highly immunized population. J Infect Dis 1996, 174:89-96.
• [14]Alberta Health: Notifiable Disease Report (NDR) Manual Sixth Edition (2013). 2013. http://www.health.alberta.ca/documents/ND-Report-Manual.pdf webcite Accessed June 25
• [15]Rodgers L, Martin SW, Cohn A, Budd J, Marcon M, Terranella A, Mandal S, Salamon D, Leber A, Tondella ML, Tatti K, Spicer K, Emanuel A, Koch E, McGlone L, Pawloski L, Lemaile-Williams M, Tucker N, Iyer R, Clark TA, Diorio M: Epidemiologic and laboratory features of a large outbreak of pertussis-like illnesses associated with cocirculating Bordetella holmesii and Bordetella pertussis–Ohio, 2010–2011. Clin Infect Dis 2013, 56:322-331.
• [16]Yih WK, Silva EA, Ida J, Harrington N, Lett SM, George H: Bordetella holmesii-like organisms isolated from Massachusetts patients with pertussis-like symptoms. Emerg Infect Dis 1999, 5:441-443.
• [17]Njamkepo E, Bonacorsi S, Debruyne M, Gibaud SA, Guillot S, Guiso N: Significant finding of Bordetella holmesii DNA in nasopharyngeal samples from French patients with suspected pertussis. J Clin Microbiol 2011, 49:4347-4348.
• [18]Zhang X, Weyrich LS, Lavine JS, Karanikas AT, Harvill ET: Lack of cross-protection against Bordetella holmesii after pertussis vaccination. Emerg Infect Dis 2012, 18:1771-1779.
• [19]Bottero D, Griffith MM, Lara C, Flores D, Pianciola L, Gaillard ME, Mazzeo M, Zamboni MI, Spoleti MJ, Anchart E, Ruggeri D, Sorhouet C, Fiori S, Galas M, Tondella ML, Hozbor DF: Bordetella holmesii in children suspected of pertussis in Argentina. Epidemiol Infect 2013, 141:714-717.
• [20]Knorr L, Fox JD, Tilley PA, hmed-Bentley J: Evaluation of real-time PCR for diagnosis of Bordetella pertussis infection. BMC Infect Dis 2006, 6(62):62.
• [21]Antila M, He Q, de JC, Aarts I, Verbakel H, Bruisten S, Keller S, Haanpera M, Makinen J, Eerola E, Viljanen MK, Mertsola J, Van der ZA: Bordetella holmesii DNA is not detected in nasopharyngeal swabs from Finnish and Dutch patients with suspected pertussis. J Med Microbiol 2006, 55:1043-1051.
• [22]Parkins MD, McNeil SA, Laupland KB: Routine immunization of adults in Canada: Review of the epidemiology of vaccine-preventable diseases and current recommendations for primary prevention. Can J Infect Dis Med Microbiol 2009, 20:e81-e90.
• [23]Skowronski DM, De SG, MacDonald D, Wu W, Shaw C, Macnabb J, Champagne S, Patrick DM, Halperin SA: The changing age and seasonal profile of pertussis in Canada. J Infect Dis 2002, 185:1448-1453.
• [24]Fisman DN, Tang P, Hauck T, Richardson S, Drews SJ, Low DE, Jamieson F: Pertussis resurgence in Toronto, Canada: a population-based study including test-incidence feedback modeling. BMC Public Health 2011, 11:694. doi:10.1186/1471-2458-11-694: 694–11 BioMed Central Full Text
• [25]Celentano LP, Massari M, Paramatti D, Salmaso S, Tozzi AE: Resurgence of pertussis in Europe. Pediatr Infect Dis J 2005, 24:761-765.
• [26]Child Health Surveillance Project Data Group.Alberta Health and Wellness: Alberta Child Health Surveillance Report 2005. 2013. http://www.health.alberta.ca/documents/Child-Health-Surveillance-05.pdf webcite Accessed May 29
• [27]Campbell P, McIntyre P, Quinn H, Hueston L, Gilbert GL, McVernon J: Increased population prevalence of low pertussis toxin antibody levels in young children preceding a record pertussis epidemic in Australia. PLoS One 2012, 7:e35874.
• [28]Shuel M, Jamieson FB, Tang P, Brown S, Farrell D, Martin I, Stoltz J, Tsang RS: Genetic analysis of Bordetella pertussis in Ontario, Canada reveals one predominant clone. Int J Infect Dis 2013, 17:e413-e417.
• [29]Public Health Agency of Canada. Pertussis. Ottawa, ON, Canada: Government of Canada; 2014. [Vaccine-Preventable Diseases]
• [30]Jackson DW, Rohani P: Perplexities of pertussis: recent global epidemiological trends and their potential causes. Epidemiol Infect 2013, 1-13. PMID is 23324361
• [31]Clark TA, Messonnier NE, Hadler SC: Pertussis control: time for something new? Trends Microbiol 2012, 20:211-213.
• [32]Misegades LK, Winter K, Harriman K, Talarico J, Messonnier NE, Clark TA, Martin SW: Association of childhood pertussis with receipt of 5 doses of pertussis vaccine by time since last vaccine dose, California, 2010. JAMA 2012, 308:2126-2132.
• [33]Wendelboe AM, Njamkepo E, Bourillon A, Floret DD, Gaudelus J, Gerber M, Grimprel E, Greenberg D, Halperin S, Liese J, Munoz-Rivas F, Teyssou R, Guiso N, Van RA: Transmission of Bordetella pertussis to young infants. Pediatr Infect Dis J 2007, 26:293-299.
• [34]Berger JT, Carcillo JA, Shanley TP, Wessel DL, Clark A, Holubkov R, Meert KL, Newth CJ, Berg RA, Heidemann S, Harrison R, Pollack M, Dalton H, Harvill E, Karanikas A, Liu T, Burr JS, Doctor A, Dean JM, Jenkins TL, Nicholson CE: Critical pertussis illness in children: a multicenter prospective cohort study. Pediatr Crit Care Med 2013, 14:356-365.
• [35]Lindsey B, Kampmann B, Jones C: Maternal immunization as a strategy to decrease susceptibility to infection in newborn infants. Curr Opin Infect Dis 2013, 26:248-253.
• [36]Terranella A, Asay GR, Messonnier ML, Clark TA, Liang JL: Pregnancy dose Tdap and postpartum cocooning to prevent infant pertussis: a decision analysis. Pediatrics 2013, 131:e1748-e1756.
• [37]Vickers D, Mainar-Jaime RC, Pahwa P: Pertussis in rural populations of Saskatchewan (1995 to 2003): incidence, seasonality, and differences among cases. Can J Public Health 2006, 97:459-464.